In today's ACT Brief, we examine how AI enables sponsors to pressure-test protocols before enrollment, HHS's multi-initiative effort to accelerate trial design and execution, and FDA approval expanding heart disease therapy to adolescents.
News|Podcasts|February 16, 2026
ACT Brief: eSource Moves Toward AI-Enabled Validation, Outsourcing Models Shift Toward Flexibility, and Robust Trial Design Becomes Mission Critical
Author(s)Andy Studna, Senior Editor
In today’s ACT Brief, we explore how eSource adoption is advancing with AI-enabled validation and interoperability, examine how flexible outsourcing models are helping sponsors balance control and efficiency, and highlight why adaptive, simulation-driven trial design is becoming essential to improving study success.
This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.
- A new ACT
FAQ outlines how EHR-to-EDC integrations are reducing manual transcription and improving data accuracy, while artificial intelligence is increasingly used to support quality checks and monitoring under human oversight. However, long-term scalability will depend on validation frameworks, regulatory alignment, and collaboration across sponsors, sites, and vendors to ensure AI-enabled workflows can be trusted and adopted at scale. - A new ACT contributor
article highlights growing adoption of the functional-service provider model, which allows sponsors to retain strategic oversight while leveraging CRO expertise to improve efficiency and resource allocation. Success depends on treating CROs as strategic partners, with strong communication and shared planning helping organizations transition without disrupting study timelines or quality standards. - Finally, a new industry
perspective emphasizes how adaptive trial designs and simulation-based planning allow sponsors to build flexibility into protocols and respond to real-world variability. By anticipating uncertainty early and adjusting designs as data emerges, sponsors can protect statistical integrity and improve the likelihood of achieving primary endpoints when outcomes matter most.
That’s all for today’s ACT Brief. Join us tomorrow for more updates shaping clinical operations and drug development. Thanks for listening.
Related to this article
In today's ACT Brief, we examine AI's role as trial design advisor with human leadership, how to govern autonomous agents in regulated operations, and real-world outcomes from switching to oral weight-loss therapy.
In today's ACT Brief, we examine how data drives honest enrollment assumptions, why RWE infrastructure lags ambition, and the disconnect between FDA rulemaking and enforcement on compounded therapies.
In today's ACT Brief, we examine what AI simulations surface in trial design, how RBQM delivers measurable financial returns, and three new FDA-approved treatments across hair loss, movement disorder, and bone disease.
In today's ACT Brief, we examine how AI is surfacing endpoint options beyond traditional design thinking, why sponsor oversight of outsourced work often fails on inspection despite being robust in practice, and a new combination drug for advanced kidney cancer.
In today's ACT Brief, we examine what patient-site relationships need beyond easier technology, how to build defensible rare disease evidence from scratch, and how real-world data and AI improve enrollment screening accuracy.
In today's ACT Brief, we examine why defensible trial data depends on traceability and platform ownership, what CGT site readiness requires as therapy moves to community care, and why data harmonization is AI's primary bottleneck.
In this episode of Beyond Compliance, Otis Johnson, PhD, MPA, founder and principal consultant at Vantix Operations, speaks with Cecilia Xi, PhD, VP of clinical and scientific affairs at Vivalink, about why defensible trial data depends on traceability, platform ownership, and device strategy long after a study ends.
Trending on Applied Clinical Trials Online
1
The Control Plane for Agentic Clinical Operations: Governing Autonomous Digital Actors in Regulated Trials
2
Hierarchical Endpoints in Cardiology: How Much Treatment Benefit, and From Where
3
HHS Launches SURPASS Program and Three Complementary Initiatives to Transform Clinical Trial Design and Infrastructure
4
What ClinOps Professionals Just Starting With AI Should Keep Top of Mind
5